Covered
TLRY · Tilray Brands, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on the last session; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $2.30, extending the decline well under the $2.69 close of 28 October 2026. A cut to the fiscal 2027 adjusted EBITDA target of $68–75 million would also break the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (1 day ago)
How picks are graded →The thesis
Tilray Brands has fallen through the $2.90 invalidation level in the previous note, closing at $2.69 on 28 October 2026, and the recovery case stays unconfirmed until second-quarter fiscal 2027 results, expected around 8 January 2027. The company reaffirmed fiscal 2027 adjusted EBITDA of $68–75 million on 8 October 2026, yet first-quarter adjusted EBITDA was $9.2 million, revenue missed estimates, and the share count keeps rising.
Adjusted EBITDA means earnings before interest, taxes, depreciation and amortization, with company adjustments. The company said results should skew to the second half, so the guidance cannot be tested before the January report. The shares are 80.7% below their 52-week high of $13.94 and fell 40.7% over three months, according to adjusted daily closes. The 14-day relative strength index (RSI), a gauge of recent selling pressure, was 11.2 on 28 October 2026, a deeply oversold reading.
The rescheduling story is close to dead as a price driver for now. A 22 October 2026 order from the DEA's administrative law judge admitted a government audit report to the record and set briefs through 5 November 2026, so no recommended decision on Schedule III can arrive before then, per Cannabis Business Times. What remains is an operating story built on beverage, international cannabis and distribution.
Bullish and bearish views on Tilray Brands, Inc.
The bull case on Tilray Brands, Inc. (TLRY), in brief: Revenue and margin grew year over year. The bear case: The price keeps breaking levels.
Bull case
- Revenue and margin grew year over year. Net revenue rose 23% to $257.1 million in the quarter ended 31 August 2026, and gross margin rose to 30% from 27%, per the company's 8 October 2026 release.
- Full-year guidance stands. The 8 October 2026 release restated adjusted EBITDA of $68–75 million for fiscal 2027, against $61.1 million in fiscal 2026. Management expects the second half, and the fourth quarter in particular, to carry the year.
- Selling is extreme. The RSI stood at 11.2 on 28 October 2026, down from 18.9 on 15 October 2026, per adjusted daily closes.
- A sell-side Buy rating remains. Roth Capital maintained its Buy rating on 27 October 2026, per a company-news headline; its target in that report was not available. Roth had upgraded the shares to Buy with a $10 target on 2 April 2026, per MarketBeat.
Bear case
- The price keeps breaking levels. The close of $2.69 on 28 October 2026 is under the $3.21 close of 15 October 2026 and under the $2.90 level in the previous note.
- Revenue missed estimates. Benzinga reported first-quarter sales of $257.1 million against an analyst estimate of $267.8 million on 8 October 2026.
- Core cannabis shrank. Cannabis revenue was $56.1 million against $64.5 million a year earlier, per the 8 October 2026 release. Beverage grew 82% to $101.5 million, which the company ties largely to the BrewDog acquisition.
- Profit slipped and the loss was large. Adjusted EBITDA was $9.2 million against $10.2 million a year earlier. Net loss was $40.0 million, or $0.32 per share.
- Dilution continues. Shares outstanding were 144.9 million at 31 August 2026, up from 131.7 million at 31 May 2026. The 14 September 2026 Form 8-K showed 2,841,650 shares issued for $12 million of 5.20% convertible notes due 15 June 2027.
- Targets are coming down. Canaccord Genuity kept Hold and cut its target to $4 on 9 October 2026, per Benzinga.
Price setup
The shares closed at $2.69 on 28 October 2026, per adjusted daily closes. That is under the $3.21 close of 15 October 2026 and the $3.61 close of 2 October 2026 cited in earlier notes. Canaccord's $4 target sits above the last close, and the 52-week high is $13.94.
Crowding evidence points to selling, not buying. The RSI of 11.2 shows heavy liquidation, and the share count has risen through note exchanges while the price fell. No SEC Form 4 insider transactions or new filings appear in the latest filing list. Earnings are not imminent, so the next scheduled company report is more than two months away.
The narrative is fading: coverage after the 8 October 2026 report, including a 19 October 2026 commentary headline calling the quarter a company "transformed", did not stop the decline.
Catalysts, next 30 days
- ~12 November 2026, est.: Hemp-derived THC recriminalization takes effect under the November 2025 spending law. Tilray said in November 2025 it expected no material revenue impact, per StockStory.
- Unscheduled: Any Form 8-K reporting further convertible-note exchanges, which add shares.
- ~8 January 2027, est.: Second-quarter fiscal 2027 results, outside the 30-day window, test the second-half earnings ramp.
Elapsed catalysts
- 29 October 2026: Optional briefs due from the DEA and seven opposing parties on the weight of the government audit report, per Cannabis Business Times. This sets the content of the final round before a recommended decision. (passed 8d ago)
- 5 November 2026: Reply briefs due; coverage says the process stays on hold until at least this date. The judge's ruling on timing follows. (passed 1d ago)
What would change the view
A cut to the fiscal 2027 adjusted EBITDA range of $68–75 million, or second-quarter adjusted EBITDA that falls short of the $9.2 million first-quarter figure, would break the case that earnings accelerate in the second half. Cannabis revenue below $56.1 million at the next report would add to that. Each of these is gradeable at the next report.
On price, a daily close below $2.30 would extend the decline well past the $2.69 close of 28 October 2026.
A rebound in the case would need second-quarter adjusted EBITDA clearly above the first quarter with guidance kept, and a halt in note-exchange share issuance. Neither has been reported.
What it trades with
Tilray trades with US cannabis policy headlines, mainly DEA rescheduling steps and hemp rules. Beverage is its largest segment, so it reacts less than pure US plant-touching operators to those headlines. Small-cap, high-debt consumer names share its sensitivity to financing costs and dilution.
Notes
- Fiscal year ends 31 May: first-quarter results land in early-to-mid October and fourth-quarter/full-year results in late July.
- The 5.20% convertible senior notes mature 15 June 2027 and are being retired through Section 3(a)(9) share exchanges, disclosed only after they close, so the share count rises in increments.
- The administrative law judge's recommendation on rescheduling is advisory; the DEA Administrator issues the final order and either side may litigate.
- Prior-year per-share figures were restated for a reverse stock split effective 2 December 2025.
- Beverage is the largest segment, which dilutes sensitivity to US cannabis policy versus pure US plant-touching operators.
Related · shared themes